NCT02953678已完成2 期
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 71
- 主要终点
- Overall Response Rate (ORR) at Day 28
研究概览
简要总结
The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies. Recipients of nonmyeloablative and myeloablative conditioning regimens are eligible.
- •Clinically suspected Grades II to IV acute GVHD as per MAGIC guidelines, occurring after allo-HSCT with any conditioning regimen and any anti-GVHD prophylactic program.
- •Subjects with steroid-refractory acute GVHD, defined as any of the following:
- •Subjects with progressive GVHD (ie, increase in stage in any organ system or any new organ involvement) after 3 days of primary treatment with methylprednisolone ≥ 2 mg/kg per day (or equivalent).
- •Subjects with GVHD that has not improved (ie, decrease in stage in at least 1 involved organ system) after 7 days of primary treatment with methylprednisolone ≥ 2 mg/kg per day (or equivalent).
- •Subjects who previously began corticosteroid therapy at a lower dose (at least 1 mg/kg per day methylprednisolone) but develop new GVHD in another organ system.
- •Subjects who cannot tolerate a corticosteroid taper, that is, begin corticosteroids at 2.0 mg/kg per day, demonstrate response, but progress before a 50% decrease from the initial starting dose of corticosteroids is achieved.
- •Evidence of myeloid engraftment (eg, absolute neutrophil count ≥ 0.5 × 10^9/L for 3 consecutive days if ablative therapy was previously used). Use of growth factor supplementation is allowed.
- •Be willing to avoid pregnancy or fathering children
排除标准
- •Has received more than 1 allo-HSCT.
- •Has received more than 1 systemic treatment in addition to corticosteroids for acute GVHD.
- •Presence of GVHD overlap syndrome as per NIH guidelines.
- •Subjects who have had a splenectomy.
- •Presence of an active uncontrolled infection. An active uncontrolled infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection. Persisting fever without signs or symptoms will not be interpreted as an active uncontrolled infection.
- •Known human immunodeficiency virus infection.
- •Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or at risk for HBV reactivation. Subjects whose immune status is unknown or uncertain must have results confirming immune status before enrollment.
- •Serum creatinine > 2.0 mg/dL or creatinine clearance < 40 mL/min measured or calculated by Cockcroft-Gault equation.
- •Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed.
- •Unresolved toxicity or complications (other than acute GVHD) due to previous allo-HSCT.
- •Any corticosteroid therapy for indications other than GVHD at doses of methylprednisolone or equivalent > 1 mg/kg per day within 7 days of enrollment.
- •Severe organ dysfunction unrelated to underlying GVHD, including:
- •Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction).
- •Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy.
- •Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.
- •Currently breast feeding.
- •Received Janus kinase inhibitor (JAK) therapy after allo-HSCT for any indication. Treatment with a JAK inhibitor before allo-HSCT is permitted.
- •Treatment with any other investigational agent, device, or procedure, within 21 days (or 5 half-lives, whichever is greater) of enrollment. Subjects participating in a GVHD prophylaxis study or conditioning regimen should be discussed with the sponsor's medical monitor before enrollment.
- •Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
- •Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
研究组 & 干预措施
Ruxolitinib in combination with corticosteroids
Experimental
Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.
干预措施: Ruxolitinib (Drug)
Ruxolitinib in combination with corticosteroids
Experimental
Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.
干预措施: Prednisone or methylprednisolone (Drug)
结局指标
主要结局
Overall Response Rate (ORR) at Day 28
时间窗: From baseline to Day 28
Defined as the percentage of participants demonstrating a complete response (CR), very good partial response (VGPR), or partial response (PR).
次要结局
- Overall Response Rate (ORR)(From baseline to days 14, 56, and 100)
- Percentage of Participants With Three-month DOR(From Baseline up to 3 months)
- Failure-free Survival (FFS)(From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months))
- Number of Participants With Treatment-emergent Adverse Events (TEAES), Serious TEAEs, And Grade 3 or Higher TEAEs(From signing the informed consent form up to 30-35 days after the last dose of study treatment (up to 24 months))
- Nonrelapse Mortality (NRM)(From baseline to Months 6, 9, 12, and 24)
- Relapse-related Mortality Rate(From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months))
- Percentage of Participants With Six-month Duration of Response (DOR)(From Baseline up to 6 months)
- Relapse Rate(From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months))
- Overall Survival (OS)(From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months))
研究者
相似试验
已完成
2 期
First Line Therapy for High Risk Acute GVHDaGVHDStem Cell Transplant ComplicationsNCT04061876Chinese PLA General Hospital198
已完成
2 期
Study of Ruxolitinib in Pancreatic Cancer PatientsPancreatic CancerNCT01423604Incyte Corporation136
终止
1 期
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPrimary MyelofibrosisMyelofibrosisNCT03373877Samus Therapeutics, Inc.4
已完成
1 期
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast CancerBreast CarcinomaHER-2 Positive Breast CancerMetastatic Breast CancerNCT02066532Dawn L. Hershman32
终止
2 期
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerNSCLC (Non-small Cell Lung Carcinoma)NCT02119650Incyte Corporation76